Xolair 300 MG/2 ML syringe 2ML
Ended Awarded
- Contract number
- SPE2DB25FDQZM
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $22,326
Award facts
- Contract value 100% obligated
- $22,325.76 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml syringes. The contract, valued at $22,325.76 with an ultimate completion date of September 16, 2025, was issued without a set-aside designation on August 25, 2025. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499.999 billion vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products and medical supplies.
Xolair (omalizumab) is a monoclonal antibody used primarily for treating moderate-to-severe persistent asthma and chronic idiopathic urticaria. This delivery order represents a discrete pharmaceutical procurement from DMS Pharmaceutical Group's expansive portfolio of branded and generic medications, biologics, and medical consumables supplied to Department of Defense healthcare facilities nationwide. The company's established status as a critical supplier in the federal pharmaceutical supply chain and its SPE2DB contract positioning enable the DLA to efficiently procure specialized pharmaceutical products to support military health system requirements.
Quick answers
Who was awarded contract SPE2DB25FDQZM?
SPE2DB25FDQZM was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 25, 2025.
How much is contract SPE2DB25FDQZM worth?
The government has obligated $22,326 on SPE2DB25FDQZM.
Is contract SPE2DB25FDQZM an order under another contract?
Yes. SPE2DB25FDQZM is a delivery order under SPE2DB24D9238, an indefinite delivery contract.
Was contract SPE2DB25FDQZM competed?
The extent of competition for SPE2DB25FDQZM was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award